Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Had the Dateline NBC vet not gone public with her decision to vacate her Today spot, Hoda Kotb might have been the one ...
Gross dollar volume rose 9% in the second quarter, while purchase volume was up 10% from one year ago. Mastercard's resilient business model hasn't just led to immense financial strength -- it's also ...
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
Filming is underway on Netflix's adaptation of Alice Feeney's His & Hers starring Tessa Thompson and Jon Bernthal.
Fox 4's Austin Schargorodski reports on a Cape Coral woman arrested for trying to sell a boat that wasn’t hers, using forged ...
Tesla extends losses following the release of third-quarter deliveries, and Levi Strauss tumbles after cutting its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback